ReviewProgress in cardiovascular diseases
Diagnosis and treatment of high density lipoprotein deficiency.
Review in Progress in cardiovascular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 87 citations in OpenAlex.
- Standardising lipid testing and reporting in the United Kingdom; a joint statement by HEART UK and The Association for Laboratory Medicine.Annals of clinical biochemistry · 2025Review
- High Density Lipoprotein Particle Composition, Functionality, Deficiency, and Atherosclerotic Cardiovascular Disease Risk: A Review.Current atherosclerosis reports · 2025Review
- The prevalence of vitamin D deficiency and its association to modifiable risk factors of cardiovascular disease among apparently healthy adults in Central Kerala.Journal of family medicine and primary care · 2025Article
- Article
- Missing in action: the genetic mysteries of extremely low HDL cholesterol.Frontiers in cardiovascular medicine · 2025Article
- Genetic and Functional Analyses of Patients with Marked Hypo-High-Density Lipoprotein Cholesterolemia.Journal of atherosclerosis and thrombosis · 2024Article
- A novel splicing variant in ABCA1 in the first reported Hong Kong Chinese patient with high-density lipoprotein deficiency.Endocrinology, diabetes & metabolism case reports · 2024Article
- Transitional Medicine of Intractable Primary Dyslipidemias in Japan.Journal of atherosclerosis and thrombosis · 2024Review
- Familial LCAT Deficiency and Low HDL-C Levels: In silico Characterization of Two Rare LCAT Missense Mutations.The application of clinical genetics · 2024Article
- Association between hypertriglyceridemic-waist phenotype and circadian syndrome risk: a longitudinal cohort study.Hormones (Athens, Greece) · 2023Article
- ABCA1 Deficiency: A Rare Cause of Premature Coronary Artery Disease.JACC. Case reports · 2023Article
- Very low HDL levels: clinical assessment and management.Archives of endocrinology and metabolism · 2023Review
- Regulation of ABCA1 by AMD-Associated Genetic Variants and Hypoxia in iPSC-RPE.International journal of molecular sciences · 2022Article
- Rare primary dyslipidaemias associated with low LDL and HDL cholesterol values in Portugal.Frontiers in genetics · 2022Article
- Proatherogenic Sialidases and Desialylated Lipoproteins: 35 Years of Research and Current State from Bench to Bedside.Biomedicines · 2021Review
- U-Shaped Association Between Serum Uric Acid Level and Hypertensive Heart Failure: A Genetic Matching Case-Control Study.Frontiers in cardiovascular medicine · 2021Article
- Bilateral Corneal Opacity of Fish-eye Disease.JMA journal · 2020Article
- [Inborn errors of high-density lipoprotein metabolism].Der Internist · 2019Review
- LCAT, ApoD, and ApoA1 Expression and Review of Cholesterol Deposition in the Cornea.Biomolecules · 2019Article
- Corneal Clouding in a Young Woman With Low HDL Cholesterol.JACC. Case reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Low serum high density lipoprotein cholesterol level (HDL-C) <40 mg/dL in men and <50 mg/dL in women is a significant independent risk factor for cardiovascular disease (CVD), and is often observed in patients with hypertriglyceridemia, obesity, insulin resistance, and diabetes. Patients with marked deficiency of HDL-C (<20 mg/dL) in the absence of secondary causes are much less common (<1% of the population). These patients may have homozygous, compound heterozygous, or heterozygous defects involving the apolipoprotein (APO)AI, ABCA1, or lecithin:cholesterol acyl transferase genes, associated with apo A-I deficiency, apoA-I variants, Tangier disease , familial lecithin:cholesteryl ester acyltransferase deficiency, and fish eye disease. There is marked variability in laboratory and clinical presentation, and DNA analysis is necessary for diagnosis. These patients can develop premature CVD, neuropathy, kidney failure, neuropathy, hepatosplenomegaly and anemia. Treatment should be directed at optimizing all non-HDL risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.